New Drug Approvals

Home » Uncategorized (Page 215)

Category Archives: Uncategorized

DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO .....FOR BLOG HOME CLICK HERE

Blog Stats

  • 4,837,790 hits

Flag and hits

Flag Counter

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 37.9K other subscribers
Follow New Drug Approvals on WordPress.com

Archives

Categories

Recent Posts

Flag Counter

ORGANIC SPECTROSCOPY

Read all about Organic Spectroscopy on ORGANIC SPECTROSCOPY INTERNATIONAL 

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 37.9K other subscribers
DR ANTHONY MELVIN CRASTO Ph.D

DR ANTHONY MELVIN CRASTO Ph.D

DR ANTHONY MELVIN CRASTO, Born in Mumbai in 1964 and graduated from Mumbai University, Completed his Ph.D from ICT, 1991,Matunga, Mumbai, India, in Organic Chemistry, The thesis topic was Synthesis of Novel Pyrethroid Analogues, Currently he is working with AFRICURE PHARMA, ROW2TECH, NIPER-G, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Govt. of India as ADVISOR, earlier assignment was with GLENMARK LIFE SCIENCES LTD, as CONSUlTANT, Retired from GLENMARK in Jan2022 Research Centre as Principal Scientist, Process Research (bulk actives) at Mahape, Navi Mumbai, India. Total Industry exp 32 plus yrs, Prior to joining Glenmark, he has worked with major multinationals like Hoechst Marion Roussel, now Sanofi, Searle India Ltd, now RPG lifesciences, etc. He has worked with notable scientists like Dr K Nagarajan, Dr Ralph Stapel, Prof S Seshadri, etc, He did custom synthesis for major multinationals in his career like BASF, Novartis, Sanofi, etc., He has worked in Discovery, Natural products, Bulk drugs, Generics, Intermediates, Fine chemicals, Neutraceuticals, GMP, Scaleups, etc, he is now helping millions, has 9 million plus hits on Google on all Organic chemistry websites. His friends call him Open superstar worlddrugtracker. His New Drug Approvals, Green Chemistry International, All about drugs, Eurekamoments, Organic spectroscopy international, etc in organic chemistry are some most read blogs He has hands on experience in initiation and developing novel routes for drug molecules and implementation them on commercial scale over a 32 PLUS year tenure till date Feb 2023, Around 35 plus products in his career. He has good knowledge of IPM, GMP, Regulatory aspects, he has several International patents published worldwide . He has good proficiency in Technology transfer, Spectroscopy, Stereochemistry, Synthesis, Polymorphism etc., He suffered a paralytic stroke/ Acute Transverse mylitis in Dec 2007 and is 90 %Paralysed, He is bound to a wheelchair, this seems to have injected feul in him to help chemists all around the world, he is more active than before and is pushing boundaries, He has 100 million plus hits on Google, 2.5 lakh plus connections on all networking sites, 100 Lakh plus views on dozen plus blogs, 227 countries, 7 continents, He makes himself available to all, contact him on +91 9323115463, email amcrasto@gmail.com, Twitter, @amcrasto , He lives and will die for his family, 90% paralysis cannot kill his soul., Notably he has 38 lakh plus views on New Drug Approvals Blog in 227 countries......https://newdrugapprovals.wordpress.com/ , He appreciates the help he gets from one and all, Friends, Family, Glenmark, Readers, Wellwishers, Doctors, Drug authorities, His Contacts, Physiotherapist, etc He has total of 32 International and Indian awards

Verified Services

View Full Profile →

Archives

Categories

Flag Counter

PHASE 1- MGL-3196 (VIA-3196)Madrigal Pharmaceuticals, to treat high cholesterol/high triglycerides


IMG_3814

MGL-3196 (VIA-3196)   photo credit The haystack  http://cenblog.org/the-haystack/tag/mgl-3196/
Madrigal Pharmaceuticals, acquired from VIA Pharmaceuticals, licensed from Roche to treat high cholesterol/high triglycerides , it mimics thyroid hormone, targeted to thyroid hormone receptor beta in the liver

Specifically, MGL-3196 is a thyroid hormone analog, designed to target a thyroid hormone receptor in the liver. These receptors regulate genes involved in cholesterol regulation and metabolism.

MGL-3196 is an orally administered, small-molecule liver-directed ß-selective THR agonist designed to specifically target receptors in the liver involved in metabolism and cholesterol regulation, and avoid side effects associated with thyroid hormone receptor activation outside the liver, including those mediated by THR-α receptors. MGL-3196 has currently completed Phase I single and multiple dose trials in healthy volunteers. MGL-3196 is being developed for dyslipidemia/hypercholesterolemia to lower LDL cholesterol, triglyceride levels and Lp(a), and was inlicensed from Roche Pharmaceuticals. MGL-3196 has excellent safety in comparative studies with other THR agonists tested previously because of MGL-3196’s high liver uptake and high ß-selectivity and nearly complete lack of THR-α activity.

MGL-3196 has completed a single ascending dose study in healthy volunteers in which the compound appeared safe at all doses tested. The multiple ascending dose study in healthy volunteers with mildly elevated LDL cholesterol was completed in October 2012 and provided additional safety and pharmacodynamic information. The Phase I multiple dose, proof of concept study enrolled 48 healthy volunteers with mildly elevated LDL cholesterol to evaluate the safety, pharmacokinetics and pharmacodynamics of MGL-3196 after two weeks of daily dosing. Results showed that MGL-3196 was well tolerated and appeared safe at all doses tested. Daily doses of 50-200 mg showed highly statistically significant reductions relative to placebo of up to 30% LDL-cholesterol (p=.05-<.0001; 28%, non-HDL cholesterol (p=.027-.0001); 24% Apolipoprotein B (p=.008-.0004); and strong trends and up to 60% reduction of triglycerides (range, p=.13-.016).

 

shark
DR ANTHONY CRASTO

phase 2-LGX818, Novartis Research Foundation to treat melanoma with a specific mutation in B-RAF kinase V600E


LGX818

Methyl [(2S)-1-{[4-(3-{5-chloro-2-fluoro-3-[(methylsulfonyl)amino]phenyl}-1-isopropyl-1H-pyrazol-4-yl)-2-pyrimidinyl]amino}-2-propanyl]carbamate

Novartis Institutes for Biomedical Research and Genomics Institute of the Novartis Research Foundation to treat melanoma with a specific mutation in B-RAF kinase  V600E,  selective mutant B-RAF kinase inhibitor

LGX818 is currently in Phase Ib/II clinical trials. Patients with colon cancer or melanoma with the BRAF mutation, including patients resistant to other BRAF-targeted drugs, are receiving LGX818 pills alone or as part of drug cocktails to determine whether the drug is safe and efficacious

A phase Ib/II drug structure by Novartis disclosed at the spring 2013 American Chemical Society meeting in New Orleans to treat melanoma with a V600E mutation in the B-RAF kinase which it inhibits.[1][2][3]

Several clinical trials of LGX818 , either alone or in combinations with the MEK inhibitorMEK162[4], CDK4 inhibitor LEE011[5] are being run. The initial results are encouraging [6].

PHASE 1-BMS-906024 by Bristol-Myers Squibb to treat breast, lung, and colon cancers and leukemia


BMS-906024 is in Phase I clinical trials, both alone and in combination with other agents. Patients with colon, lung, breast, and other cancers are receiving intravenous doses of the compound to determine its safety and optimum dose ranges

New Phase I drug structure by Bristol-Myers Squibb disclosed at the spring 2013American Chemical Society meeting in New Orleans to treat breast, lung, and colon cancers and leukemia.[1] The drug works as an pan-Notch inhibitor. The structure is one of a set patented in 2012,[2] and it currently being studied in clinical trials.[3][4]

 

Phase 2, AZD5423 BY ASTRAZENECA FOR COPD


AZD5423

The compound is now in a Phase II study in patients with COPD, where its efficacy and safety are being measured against that of a typical steroid or a placebo

A phase II drug structure by AstraZeneca disclosed at the spring 2013 American Chemical Society meeting in New Orleans to treat respiratory diseases and in particular the chronic obstructive pulmonary disease.[1][2][3][4]

 

NICE has given a provisional green light for Bayer’s blood thinner Xarelto for help patients with thrombotic events


Xarelto gains NICE thumbs up for DVT licence

NICE has given a provisional green light for Bayer’s blood thinner Xarelto for help patients with thrombotic events

NICE IS

National Institute for Health and Care Excellence

Developing a series of national clinical guidelines to secure consistent, high quality, evidence based care for patients using the National Health Service in

April 22, 2013

 

 

READ MORE AT PHARMATIMES

http://www.pharmatimes.com/Article/13-04-22/Xarelto_gains_NICE_thumbs_up_for_DVT_licence.aspx

RIVAROXABAN

Rivaroxaban (BAY 59-7939) is an oral anticoagulant invented and manufactured by Bayer; in a number of countries it is marketed as Xarelto. In the United States, it is marketed by Janssen Pharmaceutica. It is the first available orally active direct factor Xa inhibitor. Rivaroxaban is well absorbed from the gut and maximum inhibition of factor Xa occurs four hours after a dose. The effects lasts 8–12 hours, but factor Xa activity does not return to normal within 24 hours so once-daily dosing is possible. There is no specific way to reverse the anticoagulant effect of rivaroxaban in the event of a major bleeding event, unlike warfarin

In September 2008, Health Canada granted marketing authorization for rivaroxaban as one 10 mg tablet taken once daily for the prevention of venous thromboembolism (VTE) in patients who have undergone elective total hip replacement or total knee replacement surgery.

 

In September 2008, the European Commission granted marketing authorization of rivaroxaban for the prevention of venous thromboembolism in adult patients undergoing elective hip and knee replacement surgery. In December 2011 rivaroxaban has been approved by the European Commission for use in two new indications: prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors and treatment of deep vein thrombosis (DVT) and prevention of recurrent DVT and pulmonary embolism (PE) following an acute DVT in adults.

 

On July 1, 2011, the U.S. Food and Drug Administration (FDA) approved rivaroxaban for prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in adults undergoing hip and knee replacement surgery. On November 4, 2011, the U.S. FDA approved rivaroxaban for stroke prophylaxis in patients with non-valvular atrial fibrillation. On November 2, 2012, the U.S. Food and Drug Administration (FDA) approved rivaroxaban for the treatment of patients with deep vein thrombosis (DVT) and pulmonary embolism (PE) and for long-term treatment to prevent recurrence.

 

Cipla launches first Biosimilar of Etanercept in India under brand name ‘ETACEPT’


Etanercept

is made from the combination of two naturally occurring soluble human 75-kilodalton TNF receptors linked to an Fc portion of an IgG1. The effect is an artificially engineered dimeric fusion protein.

 Wed, Apr 17 2013

Cipla, the fifth largest pharma company in India with consolidated net sales of Rs.6,800 crore plus, has launched the first biosimilar of Etanercept in India; under the brand name ‘ETACEPT’ for the treatment of rheumatic disorders. Formed through a partnership alliance, ETACEPT is manufactured by a China-based company Shanghai CP Guojian Pharmaceutical Co. Ltd., which will be marketed by Cipla in India.

The introduction of Etacept now signals Cipla’s entry into the Biologic segment offering an option to the patients suffering from rheumatic disorders at a lower cost. Etacept is available as a lyophilized powder to be given by subcutaneous injection. It is available with stockists across the country at Rs.6,150 and the recommended dose for adults is 25mg twice weekly by subcutaneous injection.

READ MORE AT PHARMABIZ

http://www.pharmabiz.com/NewsDetails.aspx?aid=74842&sid=2

Etanercept (trade name Enbrel) is a biopharmaceutical that treats autoimmune diseases by interfering with tumor necrosis factor (TNF; a soluble inflammatory cytokine) by acting as a TNF inhibitor. It has U.S. F.D.A. approval to treat rheumatoid, juvenile rheumatoid andpsoriatic arthritis, plaque psoriasis and ankylosing spondylitis. TNF-alpha is the “master regulator” of the inflammatory (immune) response in many organ systems. Autoimmune diseases are caused by an overactive immune response. Etanercept has the potential to treat these diseases by inhibiting TNF-alpha.

Etanercept is a fusion protein produced by recombinant DNA. It fuses the TNF receptor to the constant end of the IgG1 antibody. First, the developers isolated the DNA sequence that codes the human gene for soluble TNF receptor 2, which is a receptor that binds to tumor necrosis factor-alpha. Second, they isolated the DNA sequence that codes the human gene for the Fc end of immunoglobulin G1 (IgG1). Third, they linked the DNA for TNF receptor 2 to the DNA for IgG1 Fc. Finally, they expressed the linked DNA to produce a protein that links the protein for TNF receptor 2 to the protein for IgG1 Fc.

The prototypic fusion protein was first synthesized and shown to be highly active and unusually stable as a modality for blockade of TNF in vivo in the early 1990s by Bruce A. Beutler, an academic researcher then at the University of Texas Southwestern Medical Center at Dallas, and his colleagues.[2][3][4] These investigators also patented the protein, selling all rights to its use to Immunex, a biotechnology company that was acquired by Amgen in 2002.

It is a large molecule, with a molecular weight of 150 kDa., that binds to TNFα and decreases its role in disorders involving excess inflammation in humans and other animals, including autoimmune diseases such as ankylosing spondylitis, juvenile rheumatoid arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and, potentially, in a variety of other disorders mediated by excess TNFα.

In North America, etanercept is co-marketed by Amgen and Pfizer under the trade name Enbrel in two separate formulations, one in powder form, the other as a pre-mixed liquid. Wyeth is the sole marketer of Enbrel outside North America excluding Japan whereTakeda Pharmaceuticals markets the drug.

Etanercept is an example of a protein-based drug created using the tools of biotechnologyand conceived through an understanding afforded by modern cell biology.

COMPANIES – India’s Orchid links up with new antibiotics firm Allecra


Indian drugmaker Orchid Pharma has bought a stake in a newly-formed European firm, Allecra Therapeutics, which has been set up to develop novel antibiotics…………………READ MORE AT PHARMATIMES

http://www.pharmatimes.com/Article/13-04-19/India_s_Orchid_links_up_with_new_antibiotics_firm_Allecra.aspx

Links

www.allecra.com
www.orchidpharma.com

The Chennai-based pharmaceuticals major, Orchid Chemicals & Pharmaceuticals Ltd,  With exports spanning more than 75 countries, it is the largest manufacturer-exporter of cephalosporin bulk actives in India and is ranked amongst the top 5 cephalosporin-producers globally.

Orchid is a first-generation enterprise founded in 1992 by K Raghavendra Rao, who is also the firm’s managing director.——- READ MORE

http://www.rediff.com/money/2004/apr/07spec.htm

Orchid Pharma MD K Raghavendra Rao

Lilly’s diabetes drug dulaglutide shines again in Phase III


Lilly's diabetes drug dulaglutide shines again in Phase III

STRUCTURAL FORMULA OF DULAGLUTIDE
Monomer
HGEGTFTSDV SSYLEEQAAK EFIAWLVKGG GGGGGSGGGG SGGGGSAESK 50
YGPPCPPCPA PEAAGGPSVF LFPPKPKDTL MISRTPEVTC VVVDVSQEDP 100
EVQFNWYVDG VEVHNAKTKP REEQFNSTYR VVSVLTVLHQ DWLNGKEYKC 150
KVSNKGLPSS IEKTISKAKG QPREPQVYTL PPSQEEMTKN QVSLTCLVKG 200
FYPSDIAVEW ESNGQPENNY KTTPPVLDSD GSFFLYSRLT VDKSRWQEGN 250
VFSCSVMHEA LHNHYTQKSL SLSLG 275
Disulfide bridges location
55-55′ 58-58′ 90-150 90′-150′ 196-254 196′-254′
MOLECULAR FORMULA C2646H4044N704O836S18
MOLECULAR WEIGHT 59.67 kDa

MANUFACTURER Eli Lilly and Company
CODE DESIGNATION LY2189265
CAS REGISTRY NUMBER 923950-08-7

http://www.ama-assn.org/resources/doc/usan/dulaglutide.pdf      FOR ALL DATA

Dulaglutide

APRIL 17, 2013

Eli Lilly has presented more promising late-stage data on its investigational long-acting diabetes drug dulaglutide.

The US major has presented top-line results from two Phase III studies from the five-trial AWARD programme. The first showed that dulaglutide demonstrated statistically superior reduction in HbA1c (blood sugar) levels compared to Sanofi’s Lantus (insulin glargine) at 52 weeks in patients with type 2 diabetes who were on metformin and glimeperide (AWARD-2). The second trial demonstrated that the drug, a once-weekly glucagon-like peptide 1 (GLP-1) receptor agonist, in combination with Lilly’s own Humalog (insulin lispro) was more effective than a Lantus/Humalog combo.

In October, Lilly posted impressive data from three other AWARD trials which showed that dulaglutide controlled HbA1c levels better than Byetta (exenatide), a drug Lilly helped develop before ending a collaboration with Amylin (since bought by Bristol-Myers Squibb and AstraZeneca), metformin and Merck & Co’s Januvia (sitagliptin).

Lilly stated that it expects to submit dulaglutide to regulatory authorities this year and present detailed data from the AWARD studies at scientific meetings in 2013 and 2014.

DRUG SPOTLIGHT- EXENATIDE, BYETTA


EXENATIDE

ACETATE CAS NO 141732-76-5

Exenatide, derived from a compound found in the saliva of the Gila monster, a large lizard native to the southwestern US, is a functional analog of Glucagon-Like Peptide-1 (GLP-1), a naturally occuring peptide.

Exenatide (INN, marketed as ByettaBydureon) is a glucagon-like peptide-1 agonist(GLP-1 agonist) medication approved in April 2005 for the treatment of diabetes mellitus type 2. It belongs to the group of incretin mimetics and is manufactured by Amylin Pharmaceuticals. Exenatide in its Byetta form is administered as a subcutaneous injection (under the skin) of the abdomen, thigh, or arm, any time within the 60 minutes before the first and last meal of the day. A once-weekly injection has been approved as of January 27, 2012 under the trademark Bydureon

Exenatide is a synthetic version of exendin-4, a hormone found in the saliva of the Gila monster that was first isolated by Dr. John Eng in 1992 while working at the Veterans Administration Medical Center in the Bronx, New York. It displays biological properties similar to human glucagon-like peptide-1 (GLP-1), a regulator of glucose metabolism andinsulin secretion. According to the package insert, exenatide enhances glucose-dependent insulin secretion by the pancreatic beta-cell, suppresses inappropriately elevated glucagon secretion, and slows gastric emptying, although the mechanism of action is still under study.

Exenatide is a 39-amino-acid peptide, an insulin secretagogue, with glucoregulatory effects. Exenatide was approved by the FDA on April 28, 2005 for patients whose diabetes was not well-controlled on other oral medication. The medication is injected subcutaneously twice per day using a filled pen-like device. The abdomen is a common injection site, after the area is cleaned with an alcohol pad. A new pen must first be tested to see if the medicine is flowing.

Gila monster

GILA MONSTER

Indication Indicated as adjunctive therapy to improve glycemic control in patients with Type 2 diabetes mellitus who are taking metformin, a sulfonylurea, or a combination of both, but have not achieved adequate glycemic control.
Pharmacodynamics Exenatide is an incretin mimetic, which has glucoregulatory effects. While it is has blood-sugar lowering actions alone, it can also be combined with other medications such as pioglitazone, metformin, sulfonylureas, and/or insulin to improve glucose control. The approved use of exenatide is with either sulfonylureas, metformin and thiazolinediones. The medication is injected twice per day using a pre-filled pen device. Typical human responses to exenatide plus eating include improvements in the initial rapid release of endogenous insulin, suppression of glucagon release by the pancreas, regulation of gastric empyting and reduced appetite; all behaviors more typical of individuals without blood sugar control problems. Exenatide is self-regulating in that in lowers blood sugar when levels are elevated but does not continue to lower blood sugar when levels return to normal, unlike with sulfonylureas or insulins.
Mechanism of action Exenatide is a functional analog of the human incretin Glucagon-Like Peptide-1 (GLP-1). Incretins enhance glucose-dependent insulin secretion and exhibit other antihyperglycemic actions following their release into the circulation from the gut. The GLP-1 system increases insulin secretion only in the presence of elevated plasma glucose levels, avoiding inappropriately high insulin levels during fasting. The drug also moderates peak serum glucagon levels during hyperglycemic periods following meals, but does not interfere with glucagon release in response to hypoglycemia. Secondary effects of drug administration reduces the rate of gastric emptying and decreases food intake, mitigating the potential severity of hyperglycemic events after meal
Following subcutaneous administration to patients with type 2 diabetes, exenatide reaches median peak plasma concentrations in 2.1 hours.

CHINESE HERBS-Ginkgo biloba for libido


Ginkgo biloba Ginkgo biloba L.

Ginkgo biloba L.
Ginkgo leaves
Common Names
Ginkgo biloba
Botanical Name
Ginkgo biloba L.
Family
GINKGOACEAE The Ginkgo family

Traditional Chinese Medicine traditional Chinese medicine The earliest know reference to ginkgo is in the Chinese Materia Medica, in apx 2,800 B.C and the seeds and root have been used in TCM for thousands of years to combat mental decline. (Ginkgo Biloba Leaf)

Ginkgo (Ginkgo biloba; in Chinese and Japanese 銀杏, pinyin romanization: yín xìng, Hepburn romanization: ichō or ginnan), also spelled gingko and known as the maidenhair tree, is a unique species of tree with no close living relatives. The ginkgo is a living fossil, recognisably similar to fossils dating back 270 million years. Native to China,the tree is widely cultivated and was introduced early to human history. It has various uses in traditional medicine and as a food.

Sexual function and responsiveness are very dependent on the supply of blood to the genital organs. In particular, enhanced blood flow to the penis can do much to improve a man’s ability to attain and maintain an erection. In this respect, the herb ginkgo biloba has much to offer.

Renowned as a circulation enhancer, ginkgo biloba was found in one study to benefit 78 per cent of men with impotence. The dose used in this study was 80mg of ginkgo biloba extract, three times a day. The beneficial effects of ginkgo biloba may take three or more months to become apparent.

Ginkgo biloba may have significant benefits for women too. There is growing awareness that improved blood supply to the female sexual organs can do much to enhance sexual sensation. While this has not been studied specifically, I have seen several patients who have experienced a subjective enhancement in sexual pleasure on taking ginkgo biloba in the long term.

The ginkgo is the oldest living tree species, geological records indicate this plant has been growing on earth for 150 – 200 million years. Chinese monks are credited with keeping the tree in existence, as a sacred herb. It was first brought to Europe in the 1700’s and it is now a commonly prescribed drug in France and Germany. It is one of the most well-researched herbs in the world.
The oldest tree species in the world, dating from the time of the dinosaurs, Ginkgo biloba (bi-loba, two sided leaf) is the last remaining species of the Ginkgoales order. Fossil records show the species was once widespread in Asia and North America, and it is speculated that it was saved from extinction by monks in the far east who cultivated it secretly as a sacred tree.

Ginkgo leaves in summer

Each tree can live for more than a thousand years, immune to bugs, disease and pollution. The tree grows to 100 feet tall and has fan-like leaves and yellow-green fetid smelling fruits. If you are lucky enough to have access to a mature tree, take advantage of the fresh leaves, which contain the broadest spectrum of medicinal properties. In the last 30 years, more that 300 studies have given clinical evidence that ginkgo prevents and benefits many problems throughout the entire body. Ginkgo is gaining recognition as a brain tonic that enhances memory because of its positive effects on the vascular system, especially in the cerebellum. It is also used as a treatment for vertigo, tinnitus (ringing in the ears) and a variety of neurological disorders and circulation problems. Ginkgo may help to counteract the effects of aging, including mental fatigue and lack of energy.

Pollen cones
Ovules

The use of the ginkgo leaf is recent, and has been studied for its cardiovascular benefits. Today ginkgo biloba is one of the most commonly prescribed herbs and is a great example of a tonic herb – one that balances whatever is going on in your system; if you are tired it can energize you, if you are stressed it will relax you.

The bilobalides, ginkgolides, flavonoids, and other substances unique to the tree restore better blood flow to all parts of the body but particularly to the brain, allowing improved use of oxygen. Ginkgo’s antioxidant actions also stabilize the structure of brain and nerve cells and protect them from oxidative attacks from free radicals. Research indicates ginkgo action of supporting healthier circulation in the eyes, make it an herb of choice for natural treatment eye health and macular degeneration.

Ginkgo works by increasing blood flow to the brain and throughout the body’s network of blood vessels that supply blood and oxygen to the organ systems. It increases metabolism efficiency, regulates neurotransmitters, and boosts oxygen levels in the brain which uses 20% of the body’s oxygen.


Benefits of enhanced circulation in the brain include improved short and long term memory, increased reaction time and improved mental clarity. Ginkgo is often used to treat elderly persons with Alzheimer’s and other symptoms of cerebral insufficiency. Cerebral insufficiency is a general term for a collection of symptoms that include difficulties of concentration and memory, absentmindedness, confusion, lack of energy, depressive mood, anxiety, dizziness, tinnitus, and headache.
Ginkgo constituents are beneficial for a variety of imbalances and deterioration in the brain and body. Standardized ginkgo extract inhibits platelet activity factor (PAF), which is a common allergen in the body. Physical stress, and poor quality food can overstimulate PAF production; in other words, blood clotting. Excessive PAF can help cause cardiovascular disease, brain damage, hearing disorders and other immune and inflammatory diseases.


Ginkgo has been used to relieve tension and anxiety and improve mental alertness, elevate mood and restore energy.
Ginkgo has two groups of active substances, flavonoids and terpene lactones, including ginkgolides A, B, and C, bilobalide, quercetin, and kaempferol. The ginkgolides have been shown to control allergic inflammation, anaphylactic shock and asthma.
Ginkgo also acts as a powerful antioxidant and contributes to the oxidation of free radicals which are believed to contribute to premature aging and dementia. Antioxidants also protect the eyes, cardiovascular system and central nervous system.
Ginkgo may also help control the transformation of cholesterol to plaque associated with the hardening of arteries, and can relax constricted blood vessels.
The herb has been used in treatment of other circulation-related disorders such as diabetic peripheral vascular disease, Raynaud’s syndrome, hemorrhoids and varicose veins. It can also aid in the treatment of insufficient circulation and complications from stroke and skull injuries. Ginkgo’s beneficial effects on the circulatory system also can be of benefit in the treatment of eye and ear disorders.
Studies have confirmed that ginkgo increases blood flow to the retina, and can slow retinal deterioration resulting in an increase of visual acuity. In clinical tests ginkgo has improved hearing loss in the elderly. It also improves circulation in the extremities relieving cold hands and feet, swelling in the limbs and chronic arterial blockage. Among other things, ginkgo is being investigated as a potential treatment to prevent the rejection of transplanted organs, as a treatment for asthma and for toxic shock syndrome.
Parts Used: Dried leaf.
Common Use: Ginkgo has been shown to be nutritional support for mental alertness, enhanced vitality level, circulatory health and blood vessel health. Its high antioxidant activity is valuable for fighting age related conditions. All over the world, people have claimed Ginkgo to be beneficial in the fight against the gradual erosion of energy associated with aging.
Care: The ginkgo tree thrives in full sun and average soil. It is very resistant to infection and pollution and can grow up to 120 feet. The small yellow fruit that falls from the female tree has a strong rancid odor